US Bancorp DE acquired a new stake in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) during the first quarter, according to its most recent filing with the SEC. The firm acquired 1,153 shares of the biopharmaceutical company’s stock, valued at approximately $130,000.

A number of other large investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in Intercept Pharmaceuticals by 20.2% in the fourth quarter. State Street Corp now owns 751,027 shares of the biopharmaceutical company’s stock valued at $81,600,000 after buying an additional 126,011 shares during the period. Norges Bank acquired a new stake in Intercept Pharmaceuticals during the fourth quarter valued at $17,652,000. Bank of Montreal Can raised its stake in Intercept Pharmaceuticals by 119.7% in the first quarter. Bank of Montreal Can now owns 24,977 shares of the biopharmaceutical company’s stock valued at $2,824,000 after buying an additional 13,606 shares during the period. State Board of Administration of Florida Retirement System raised its stake in Intercept Pharmaceuticals by 2.5% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 23,736 shares of the biopharmaceutical company’s stock valued at $2,579,000 after buying an additional 589 shares during the period. Finally, Teachers Advisors LLC raised its stake in Intercept Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 15,410 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 1,339 shares during the period. Hedge funds and other institutional investors own 84.35% of the company’s stock.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at 132.29 on Friday. The firm’s market cap is $3.31 billion. The company has a 50-day moving average of $116.91 and a 200-day moving average of $114.33. Intercept Pharmaceuticals, Inc. has a 1-year low of $96.63 and a 1-year high of $177.93.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($4.27) by $0.66. The firm had revenue of $21 million during the quarter, compared to analysts’ expectations of $15.88 million. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The business’s revenue for the quarter was up 4566.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($5.17) earnings per share. Analysts predict that Intercept Pharmaceuticals, Inc. will post ($14.50) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “1,153 Shares in Intercept Pharmaceuticals, Inc. (ICPT) Acquired by US Bancorp DE” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/1153-shares-in-intercept-pharmaceuticals-inc-icpt-acquired-by-us-bancorp-de/1389614.html.

ICPT has been the topic of several research reports. Cantor Fitzgerald set a $60.00 price objective on shares of Intercept Pharmaceuticals and gave the stock a “sell” rating in a research note on Thursday, May 4th. Wedbush reiterated a “positive” rating and set a $224.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, February 24th. Laidlaw upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 price objective on the stock in a research note on Friday, May 5th. Cowen and Company reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, June 12th. Finally, ValuEngine upgraded shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $190.98.

In related news, CMO David Shapiro sold 346 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $115.00, for a total transaction of $39,790.00. Following the completion of the transaction, the chief marketing officer now owns 46,023 shares in the company, valued at $5,292,645. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Lisa Bright sold 698 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $110.73, for a total transaction of $77,289.54. Following the transaction, the insider now owns 24,711 shares of the company’s stock, valued at approximately $2,736,249.03. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,016 shares of company stock valued at $452,624. Corporate insiders own 9.20% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.